Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.
Diagnosis & Disease Information
Docetaxel-associated Myalgia-arthralgia Syndrome in Patients With Breast Cancer
[Breast Cancer: Targets and Therapy] This research examines possible risk factors and effectiveness of treatments for docetaxel-associated myalgia-arthralgia syndrome.
Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
[Breast Cancer: Targets and Therapy] This research examines predisposing factors, prevention, and therapy of myalgia-arthralgia syndrome (M-AS).
Cognitive Impairment Common With Adjuvant Therapy in Older Patients With Early Stage Breast Cancer
Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.
Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer
Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.
Can docetaxel cause intoxication in cancer patients?
The FDA issued an alert last Friday that some patients have reported feeling intoxicated after receiving their infusions of the chemotherapeutic drug, docetaxel.
Study Results Demonstrate A New Prostate Cancer Treatment
A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.
Zytiga approved for metastatic prostate cancer
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
Some breast cancers may respond to anti-androgen drug
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
Noninvasive technique predicts patients’ response to chemotherapy
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
- Loading...
Loading...
Loading... 
Loading...